China is a region with high incidence of liver cancer. The incidence of liver cancer accounts for more than 50% of the global incidence. As early as in the "Shengnong Herbal Classic" recorded: " warms qi in the middle, pain relief, cough against cold and heat, dehumidification, blood bi, wind evil, open Zou Li." Modern pharmacological studies have shown that Evodiamine can significantly inhibit the proliferation of cancer cells, promote the apoptosis of cancer cells, block the cycle of cancer cells, and inhibit the invasion and metastasis of liver cancer cells. At present, studies on the mechanism of Evodiamine's anti-liver cancer action mainly focus on several pathways, and most of them are cell and animal experiments. The effective components and dose-effect relationship of Evodiamine against tumor are not perfect, and relevant studies on drug-fast and body immunity are lacking. In the future, the above points can be further studied to provide a new scientific basis for clinical application.

Junwei Li, Junxuan Chen. Research Progress on the Mechanism of Evodiamine against Hepatocarcinoma. Frontiers in Medical Science Research (2023) Vol. 5, Issue 8: 74-78. https://doi.org/10.25236/FMSR.2023.050810.

[1] Zhang Siwei, Zheng Rongshou, Sun Kexin, et al. Regional incidence and mortality estimation of malignant tumors in China in 2016: Analysis based on population-based cancer registry data [J]. Chinese Journal of Oncology, 2023. 

[2] Ni Yuchun, Zhao Hongyan, Wang Xixing. The theoretical basis and guiding significance of treating liver cancer from the perspective of the spleen [J]. Journal of Zhejiang Chinese Medical University, 2012. 

[3] Zhang Shucai. Study on the Prescription Medication Regularity of Treating Liver Cancer with Tonifying the Spleen and Qi-Benefiting Method and Its Impact on Tumor Microenvironment [D]. Beijing University of Chinese Medicine, 2019. 

[4] Jin Huimin, Xiang Yuying, Feng Yuqian, et al. The Regularity of Using Medicinal Formula Ye Tianshi in Cancer Treatment Based on Data Mining [J]. Chinese Rural Medicine, 2020. 

[5] Che-Yuan Hu, Hung-Tsung Wu, Yu-Chu Su, et al. Evodiamine Exerts an Anti-Hepatocellular Carcinoma Activity through a WWOX-Dependent Pathway[J]. Molecules, 2017, 22: 1175. 

[6] Li Yupu, Wu Chun-Chieh, Chen Wan-Tzu. The expression and significance of WWOX and β-catenin in hepatocellular carcinoma. [J]. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica, 2012, (2): 120-6. 

[7] Wen Zhenzhen, Feng Shujiong, Wei Lijuan. Evodiamine, a novel inhibitor of the Wnt pathway, inhibits the self-renewal of gastric cancer stem cells. [J]. International journal of molecular medicine, 2015, (6): 1657-63. 

[8] Dongjun Luo, Zhongxia Wang, Junyi Wu, et al. The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma [J]. Biomed Research International, 2014, 2014: 409272. 

[9] Yangling Li, Ningyu Zhang, Xiu Hu, et al. Evodiamine induces apoptosis and promotes hepatocellular carcinoma cell death induced by vorinostat via downregulating HIF-1α under hypoxia[J]. Biochemical and Biophysical Research Communications, 2018, 498: 481-486. 

[10] Decheng Chao, Lijen Lin, Shungte Kao, et al. Inhibitory effects of Zuo-Jin-Wan and its alkaloidal ingredients on activator protein 1, nuclear factor-κB, and cellular transformation in HepG2 cells[J]. Fitoterapia, 2011, 82: 696-703. 

[11] Zhao Shuang. Regulation of Liver Cancer Cell Proliferation and Apoptosis by Wuzhuyu Alkaloid through the Hippo-YAP Signaling Pathway [D]. Chongqing Medical University, 2020. 

[12] Zhao Shuang, Guo Xingxian, Zhou Peng, et al. Experimental Study on Induction of Apoptosis in Human Liver Cancer BEL-7402 Cells by Wuzhuyu Alkaloid through the Hippo-YAP Pathway [J]. Chinese Herbal Medicines, 2019, 50(20): 4962-4968. 

[13] Brown R. The bcl-2 family of proteins. [J]. British medical bulletin, 1997, (3): 466-77. 

[14] Sujin Bae, Yu-Rim Song and Young-Woo Kim * Un-Jung Yun †. A Critical YAP in Malignancy of HCC Is Regulated by Evodiamine [Z], 2021: 1-12. 

[15] Li Caiyun. Induction of Proliferation Inhibition and Apoptosis in Liver Cancer Cells by Wuzhuyu Alkaloid through the MAPK Pathway [D]. Guangzhou University of Chinese Medicine, 2019. 

[16] Xingxian Guo, Xiaopeng Li, Peng Zhou, et al. Evodiamine Induces Apoptosis in SMMC-7721 and HepG2 Cells by Suppressing NOD1 Signal Pathway[J]. International Journal of Molecular Sciences, 2018, 19: 3419. 

[17] Guo Xingxian, Li Xiaopeng, Lv Xiaoting, et al. Induction of Apoptosis in HepG2 and SMMC-7721 Liver Cancer Cells by Wuzhuyu Alkaloid through Inhibition of the NOD1 Pathway [J]. Chinese Pharmacological Bulletin, 2018, 34(11): 1588-1593. 

[18] Fan Yang, Le Shi, Tao Liang, et al. Anti-tumor effect of evodiamine by inducing Akt-mediated apoptosis in hepatocellular carcinoma[J]. Biochemical and Biophysical Research Communications, 2017, 485: 54-61. 

[19] Hu Xiaoyi, Li Jing, Fu Maorong. The JAK/STAT signaling pathway: from bench to clinic. [J]. Signal transduction and targeted therapy, 2021, (1): 402. 

[20] Jie Yang, Xueting Cai, Wuguang Lu, et al. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells[J]. Cancer Letters, 2013, 328: 243-251. 

[21] Hanzhang Zhu, Ke Ge, Jun Lu, et al. Growth inhibitor of human hepatic carcinoma HepG2 cells by evodiamine is associated with downregulation of PRAME[J]. Naunyn-schmiedeberg's Archives of Pharmacology, 2019, 392: 1551-1560. 

[22] Fang Lei, Yongxia Xiong, Yuqing Wang, et al. Design, Synthesis, and Biological Evaluation of Novel Evodiamine Derivatives as Potential Antihepatocellular Carcinoma Agents[J]. Journal of Medicinal Chemistry, 2022, 65(11): 7975-7992. 

[23] Xiaohong Fan, Jiedan Deng, Tao Shi, et al. Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma[J]. Bioorganic Chemistry, 2021, 114: 105154.